Publications by authors named "Keigo Amaya"
Article Synopsis
- Phyllodes tumors of the breast are classified into benign, borderline, or malignant based on criteria set by the WHO, focusing on factors like stromal cell characteristics and mitotic count.
- A study evaluated various proliferation markers, including Ki-67 and mitotic count, across 76 phyllodes tumors to determine which marker is most effective in distinguishing between tumor types.
- Results indicated that mitotic count was the most reliable marker for differentiating malignant tumors from benign or borderline ones, while other criteria are also important for distinguishing between benign and borderline tumors.
Development of a myxofibrosarcoma in the breast tissue is extremely rare. Reported here is a case of myxofibrosarcoma found in the left breast tissue of a male in his late fifties. The patient first underwent tumor resection, followed by a left mastectomy with the reconstruction of the vastus lateralis valve.
View Article and Find Full Text PDFPatients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative/Ki-67-high (ER+HER2-Ki-67high) luminal breast cancer have a worse prognosis and do not respond to hormonal treatment and chemotherapy. This study sought to identify disease-related protein networks significantly associated with this subtype, by assessing in-depth proteomes of 10 lesions of high and low Ki-67 values (HOT, five; COLD, five) microdissected from the five tumors. Weighted correlation network analysis screened by over-representative analysis identified the five modules significantly associated with the HOT lesions.
View Article and Find Full Text PDF